HIV Vaccine Successful in Human Trials
A new vaccine developed by Canadian researchers to prevent HIV has passed the first phase of human testing.
According to the Ontario Business Report, the team, from the Schulich School of Medicine & Dentistry at Western University, succeeded on the first phase of trials, even boosting the production of antibodies in patients it was tested on.
Lead researcher Dr. Chil-Yong Kang said the vaccine is based on a genetically-modified ‘dead’ version of the virus.
“We infect the cells with a genetically modified HIV-1,” team leader Dr. Chil-Yong Kang told Ontario Business Report. “The infected cells produce lots of virus, which we collect, purify and inactivate so that the vaccine won’t cause AIDS in recipients, but will trigger immune responses.”
Sumagen, the South Korean biotech firm sponsoring the vaccine, said that if all goes well in trials, it could be commercially available in five years.
“We are now prepared to take the next steps towards Phase II and Phase III clinical trials,” CEO Jung-Gee Cho said in a press release. “We are opening the gate to pharmaceutical companies, government, and charity organization for collaboration to be one step closer to the first commercialized HIV vaccine.”